GSK’s Nucala, an anti-IL5 biologic, has shown positive results in a Phase III clinical trial for treating COPD. The drug met its primary endpoint, demonstrating a significant reduction in exacerbations when added to standard therapy. This development positions Nucala as a potential treatment option for COPD patients, especially those with type II inflammation.
GSK’s Nucala, an IL-5 inhibitor, has demonstrated positive results in the MATINEE Phase 3 trial for treating Chronic Obstructive Pulmonary Disease (COPD). The drug significantly reduced the rate of moderate/severe exacerbations in patients with type 2 inflammation, offering hope for a new treatment option for this widespread respiratory disease.
